Respiratory Bronchiolitis with Fibrosis: Prevalence and Progression

English, Collette; Churg, Andrew; Lam, Stephen; Bilawich, Ana-Maria

doi:10.1513/annalsats.201410-474le

Cited by 3 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pulmonary fibrosis (PF), characterized by fibroblast proliferation and aggregation of large amounts of extracellular matrix components in the interstitium, is a progressive, chronic, fatal lung disease characterized by inflammatory tissue damage and respiratory function failure. [1][2][3][4][5][6] Nalysnyk et al found that PF is common worldwide. In Europe, the PF prevalence ranged from 1.25 to 23.4 cases per 100 000 subjects and in the USA, the annual incidence was 6.8 to 8.8 cases per 100 000 subjects.…”

Section: Introductionmentioning

confidence: 99%

Upregulated has-miR-4516 as a potential biomarker for early diagnosis of dust-induced pulmonary fibrosis in patients with pneumoconiosis

Huang

Liu

et al. 2018

Toxicol. Res.

View full text Add to dashboard Cite

: Pulmonary fibrosis (PF) is a representative pathological change in patients with pneumoconiosis; however, due to the absence of reliable and early biomarkers, microRNAs have recently emerged as potential candidates for identification. : The aim of our study was to discover the potential of PF-specific circulating microRNAs as early biomarkers among patients with pneumoconiosis.: Four dust-exposed patients with PF and four matched healthy individuals (not exposed to dust) were recruited for the study. microRNA profiling was identified by micro-array and bioinformatics methods. Gene Ontology (GO) analysis was used to identify the potential biological or molecular processes modulated by these miRNAs. Kyoto Encyclopedia of Genes and Genomes pathway (KEGG) analysis was used to identify the potentially involved signaling pathways. miRNA-mRNA-binding network analysis was employed to identify genes potentially targeted by the miRNAs. : 1079 miRNAs were discovered, of which 406 were up-regulated and 117 were down-regulated in PF patients. 32 miRNAs were up-regulated by>4-fold and 17 miRNAs were down-regulated by >0.5 fold. GO analysis identified the biological processes affected by anatomical structure development, hemophilic cell adhesion and cell-cell adhesion plasma membrane proteins. Target prediction software showed that serum has-miR-4516 targeted genes encoding basonuclin2, inhibitors of growth family member 4, the potassium voltage-gated channel, and "sha-1-related subfamily member 1" proteins. qRT-PCR revealed that has-miR-4516 was a potential biomarker of PF progression in patients with pneumoconiosis.: Our findings suggest that the level of serum miR-4516 may be a potential biomarker for early diagnosis of PF in patients with pneumoconiosis. This is a pilot work that paves the way for a further functional study of the underlying regulatory mechanisms.

show abstract

Section: Introductionmentioning

confidence: 99%

Upregulated has-miR-4516 as a potential biomarker for early diagnosis of dust-induced pulmonary fibrosis in patients with pneumoconiosis

Huang

Liu

et al. 2018

Toxicol. Res.

View full text Add to dashboard Cite

show abstract

Computed tomography of smoking-related lung disease: review and update

2015

View full text Add to dashboard Cite

Smoking-Related Interstitial Fibrosis: Evidence of Radiologic Regression with Advancing Age and Smoking Cessation

Fabre

Treacy

Lavelle

et al. 2017

COPD: Journal of Chronic Obstructive Pulmonary Disease

View full text Add to dashboard Cite

More data are needed regarding the radiology, co-morbidities and natural history of smoking-related interstitial fibrosis (SRIF), a common pathological finding, mainly described heretofore in association with lung cancer, where respiratory bronchiolitis (RB) usually co-exists. We prospectively acquired high resolution CT scan data (edge-enhancing lung reconstructions) to detect any radiologic interstitial lung abnormality (ILA) in individuals who ultimately underwent surgical lobectomy for lung cancer (n = 20), for radiologic/pathologic correlation. We also re-examined other smoking-related benign histologic cases: chronic obstructive pulmonary disease (COPD lung explants, n = 20), alpha 1-antitrypsin deficiency (A1AT, explanted lungs n = 20), combined pulmonary fibrosis and emphysema (CPFE, n = 8) and idiopathic pulmonary fibrosis (IPF, n = 10). Finally, we pooled our data with all peer-reviewed published data describing histologic SRIF of known ILA status. SRIF was observed in 40% of cancer lobectomies, mean (±SD) age 65.8 ± 8.7 years, none of whom had ILA. SRIF was observed in other smoking-related benign diseases (COPD 35%, A1AT 20%, CPFE 25%, and IPF 10%). 71.4% of benign SRIF cases had no RB (nearly all ex-smokers) versus 0% of cancer-associated SRIF cases (P = 1.7 × 10). Pooled data showed that those SRIF subjects without ILA were 15.05 years older than those with ILA (95% confidence interval 8.99 to 21.11, P = 2.5 × 10) and more likely to be former smokers (P = 7.2 × 10). SRIF is frequently found without lung cancer, and mostly without RB in former smokers. SRIF is less likely to have ILA in older subjects and with smoking cessation, which could represent RB+/-SRIF regression.

show abstract

Respiratory Bronchiolitis with Fibrosis: Prevalence and Progression

Cited by 3 publications

References 8 publications

Upregulated has-miR-4516 as a potential biomarker for early diagnosis of dust-induced pulmonary fibrosis in patients with pneumoconiosis

Upregulated has-miR-4516 as a potential biomarker for early diagnosis of dust-induced pulmonary fibrosis in patients with pneumoconiosis

Computed tomography of smoking-related lung disease: review and update

Smoking-Related Interstitial Fibrosis: Evidence of Radiologic Regression with Advancing Age and Smoking Cessation

Contact Info

Product

Resources

About